Expression of Concern: Cell-Associated Flagella Enhance the Protection Conferred by Mucosally-Administered Attenuated Salmonella Paratyphi A Vaccines (PLoS Negl Trop Dis, (2011), 5, 11, e1373 10.1371/journal.pntd.0001373);Cell-associated flagella enhance the protection conferred by mucosally-administered attenuated Salmonella paratyphi A vaccines

PLoS Neglected Tropical Diseases

Volumn 5, Issue 11, 2011, Pages

  Gat, Orit ^a,b   Galen, James E ^a,b   Tennant, Sharon ^a,b   Simon, Raphael ^a,b   Blackwelder, William C ^a,b   Silverman, David J ^b   Pasetti, Marcela F ^a,b   Levine, Myron M ^a,b  

^a University of Maryland School of Medicine Center for Vaccine Development   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; BACTERIAL VACCINE; FC RECEPTOR; FLAGELLIN; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; PROTEIN ANTIBODY; PROTEIN FLGK; PROTEIN FLID; UNCLASSIFIED DRUG; BACTERIUM ANTIBODY; IMMUNOGLOBULIN G; LIVE VACCINE; OPSONIN; SALMONELLOSIS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL CELL; BACTERIAL CLEARANCE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIAL VIRULENCE; CHROMOSOME DELETION; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FLAGELLUM; FLGK GENE; FLID GENE; GENE DELETION; GENE LOCUS; HOST PATHOGEN INTERACTION; HUMAN; IMMUNIZATION; IMMUNOGENICITY; IN VIVO STUDY; LD 50; MOUSE; NONHUMAN; OPSONOPHAGOCYTOSIS; PARATYPHOID FEVER; PHAGOCYTOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SALMONELLA PARATYPHI; WILD TYPE; ANIMAL; BAGG ALBINO MOUSE; BLOOD; DISEASE MODEL; GENETICS; IMMUNOLOGY; SURVIVAL; VIRULENCE;

ANIMALS; ANTIBODIES, BACTERIAL; DISEASE MODELS, ANIMAL; FEMALE; FLAGELLA; GENE DELETION; IMMUNOGLOBULIN G; LETHAL DOSE 50; MICE; MICE, INBRED BALB C; OPSONIN PROTEINS; PARATYPHOID FEVER; PHAGOCYTOSIS; SALMONELLA PARATYPHI A; SALMONELLA VACCINES; SURVIVAL ANALYSIS; VACCINES, ATTENUATED; VIRULENCE;

EID: 82555173723     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0012160     Document Type: Erratum

References (60)

1. Vollaard AM, Ali S, Widjaja S, Asten HA, Visser LG, et al. (2005) Identification of typhoid fever and paratyphoid fever cases at presentation in outpatient clinics in Jakarta, Indonesia. Trans R Soc Trop Med Hyg 99: 440-450.
2. Ochiai RL, Wang X, von SL, Yang J, Bhutta ZA, et al. (2005) Salmonella paratyphi A rates, Asia. Emerg Infect Dis 11: 1764-1766.
3. Karkey A, Aryjal A, Basnyat B, Baker S, (2008) Kathmandu, Nepal: still an enteric fever capital of the world. J Infect Dev Ctries 2: 461-465.
4. Gupta SK, Medalla F, Omondi MW, Whichard JM, Fields PI, et al. (2008) Laboratory-based surveillance of paratyphoid fever in the United States: travel and antimicrobial resistance. Clin Infect Dis 46: 1656-1663.
5. Levine MM, Taylor DN, Ferreccio C, (1989) Typhoid vaccines come of age. Pediatr Infect Dis J 8: 374-381.
6. Lin FYC, Ho VA, Khiem HB, Trach DD, Bay PVTTC, et al. (2001) The efficacy of a Salmonella Typhi Vi conjugate vaccine in two-to-five-year-old children. N Eng J Med 344: 1263-1268.
7. Mai NL, Phan VB, Vo AH, Tran CT, Lin FY, et al. (2003) Persistent efficacy of Vi conjugate vaccine against typhoid fever in young children. N Engl J Med 349: 1390-1391.
8. Levine MM, Ferreccio C, Black RE, Lagos R, San MO, et al. (2007) Ty21a live oral typhoid vaccine and prevention of paratyphoid fever caused by Salmonella enterica Serovar Paratyphi B. Clin Infect Dis 45 (Suppl 1): S24-S28.
9. Simanjuntak C, Paleologo F, Punjabi N, Darmowitogo R, Soeprawato, et al. (1991) Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine. Lancet 338: 1055-1059.
10. Ruan P, Xia XP, Sun D, Ojcius DM, Mao YF, et al. (2008) Recombinant S. Paratyphi A O and H1a as immunogens for protection of mice from lethal infection with Salmonella paratyphi A: implications for rational design of typhoid fever vaccines. Vaccine 26: 6639-6644.
11. Roland KL, Tinge SA, Kochi SK, Thomas LJ, Killeen KP, (2010) Reactogenicity and immunogenicity of live attenuated Salmonella enterica serovar Paratyphi A enteric fever vaccine candidates. Vaccine 28: 3679-3687.
12. Zhang XL, Jeza VT, Pan Q, (2008) Salmonella: from a human pathogen to a vaccine vector. Cell Mol Immunol 5: 91-97.
13. Huleatt JW, Nakaar V, Desai P, Huang Y, Hewitt D, et al. (2008) Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine 26: 201-214.
14. Bargieri DY, Leite JA, Lopes SC, Sbrogio-Almeida ME, Braga CJ, et al. (2010) Immunogenic properties of a recombinant fusion protein containing the C-terminal 19 kDa of Plasmodium falciparum merozoite surface protein-1 and the innate immunity agonist FliC flagellin of Salmonella typhimurium. Vaccine 28: 2818-2826.
15. Treanor JJ, Taylor DN, Tussey L, Hay C, Nolan C, et al. (2010) Safety and immunogenicity of a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125) in healthy young adults. Vaccine 28: 8268-8274.
16. Ikeda T, Homma M, Iino T, Asakura S, Kamiya R, (1987) Localization and stoichiometry of hook-associated proteins within Salmonella typhimurium flagella. J Bacteriol 169: 1168-1173.
17. Homma M, Kutsukake K, Iino T, Yamaguchi S, (1984) Hook-associated proteins essential for flagellar filament formation in Salmonella typhimurium. J Bacteriol 157: 100-108.
18. Ikeda T, Kamiya R, Yamaguchi S, (1984) In vitro polymerization of flagellin excreted by a short-flagellum Salmonella typhimurium mutant. J Bacteriol 159: 787-789.
19. Homma M, Iino T, Kutsukake K, Yamaguchi S, (1986) In vitro reconstitution of flagellar filaments onto hooks of filamentless mutants of Salmonella typhimurium by addition of hook-associated proteins. Proc Natl Acad Sci U S A 83: 6169-6173.
20. Homma M, Fujita H, Yamaguchi S, Iino T, (1984) Excretion of unassembled flagellin by Salmonella typhimurium mutants deficient in hook-associated proteins. J Bacteriol 159: 1056-1059.
21. Vonderviszt F, Imada K, Furukawa Y, Uedaira H, Taniguchi H, et al. (1998) Mechanism of self-association and filament capping by flagellar HAP2. J Mol Biol 284: 1399-1416.
22. Datsenko KA, Wanner BL, (2000) One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc Natl Acad Sci U S A 97: 6640-6645.
23. Galen JE, Wang JY, Chinchilla M, Vindurampulle CJ, Vogel JE, et al. (2010) A new generation of stable, nonantibiotic, low-copy-number plasmids improves immune responses to foreign antigens in Salmonella enterica serovar Typhi live vectors. Infect Immun 78: 337-347.
24. Tomoyasu T, Takaya A, Isogai E, Yamamoto T, (2003) Turnover of FlhD and FlhC, master regulator proteins for Salmonella flagellum biogenesis, by the ATP-dependent ClpXP protease. Mol Microbiol 48: 443-52.
25. Monsigny M, Petit C, Roche AC, (1988) Colorimetric determination of neutral sugars by a resorcinol sulfuric acid micromethod. Anal Biochem 175: 525-530.
26. Wang JY, Pasetti MF, Noriega FR, Anderson RJ, Wasserman SS, Galen JE, et al. (2001) Construction, genotypic and phenotypic characterization, and immunogenicity of attenuated ΔguaBA Salmonella enterica serovar Typhi strain CVD 915. Infect Immun 69: 4734-4741.
27. Powell CJ Jr, DeSett CR, Lowenthal JP, Berman S, (1980) The effect of adding iron to mucin on the enhancement of virulence for mice of Salmonella typhi strain TY 2. J Biol Stand 8: 79-85.
28. Tennant SM, Wang JY, Galen JE, Simon R, Pasetti MF, et al. (2011) Engineering and pre-clinical evaluation of attenuated non-typhoidal Salmonella strains serving as live oral vaccines and as reagent strains. Infect Immun In press.
29. Harshey RM, Matsuyama T, (1994) Dimorphic transition in Escherichia coli and Salmonella typhimurium: surface-induced differentiation into hyperflagellate swarmer cells. Proc Natl Acad Sci U S A 91: 8631-8635.
30. Hone DM, Harris AM, Chatfield S, Dougan G, Levine MM, (1991) Construction of genetically-defined double aro mutants of Salmonella typhi. Vaccine 9: 810-816.
31. Tacket CO, Hone DM, Losonsky GA, Guers L, Edelman R, et al. (1992) Clinical acceptability and immunogenicity of CVD 908 Salmonella typhi vaccine strain. Vaccine 10: 443-446.
32. Tacket CO, Sztein MB, Wasserman SS, Losonsky G, Kotloff KL, et al. (2000) Phase 2 clinical trial of attenuated Salmonella enterica serovar Typhi oral live vector vaccine CVD 908-htrA in U.S. volunteers. Infect Immun 68: 1196-1201.
33. McClelland M, Sanderson KE, Clifton SW, Latreille P, Porwollik S, et al. (2004) Comparison of genome degradation in Paratyphi A and Typhi, human-restricted serovars of Salmonella enterica that cause typhoid. Nat Genet 36: 1268-1274.
34. Gillen KL, Hughes KT, (1991) Negative regulatory loci coupling flagellin synthesis to flagellar assembly in Salmonella typhimurium. J Bacteriol 173: 2301-2310.
35. Pickett TE, Pasetti MF, Galen JE, Sztein MB, Levine MM, (2000) In vivo characterization of the murine intranasal model for assessing the immunogenicity of attenuated Salmonella enterica serovar Typhi strains as live mucosal vaccines and as live vectors. Infect Immun 68: 205-213.
36. Galen JE, Gomez-Duarte OG, Losonsky GA, Halpern JL, Lauderbaugh CS, et al. (1997) A murine model of intranasal immunization to assess the immunogenicity of attenuated Salmonella typhi live vector vaccines in stimulating serum antibody responses to expressed foreign antigens. Vaccine 15: 700-708.
37. Wang JY, Noriega FR, Galen JE, Barry E, Levine MM, (2000) Constitutive expression of the Vi polysaccharide capsular antigen in attenuated Salmonella enterica serovar Typhi oral vaccine strain CVD 909. Infect Immun 68: 4647-4652.
38. Heusser CH, Anderson CL, Grey HM, (1977) Receptors for IgG: subclass specificity of receptors on different mouse cell types and the definition of two distinct receptors on a macrophage cell line. J Exp Med 145: 1316-1327.
39. Klaus GG, Pepys MB, Kitajima K, Askonas BA, (1979) Activation of mouse complement by different classes of mouse antibody. Immunology 38: 687-695.
40. Kipps TJ, Parham P, Punt J, Herzenberg LA, (1985) Importance of immunoglobulin isotype in human antibody-dependent, cell-mediated cytotoxicity directed by murine monoclonal antibodies. J Exp Med 161: 1-17.
41. Hayashi F, Smith KD, Ozinsky A, Hawn TR, Yi EC, et al. (2001) The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 410: 1099-1103.
42. Feuillet V, Medjane S, Mondor I, Demaria O, Pagni PP, et al. (2006) Involvement of Toll-like receptor 5 in the recognition of flagellated bacteria. Proc Natl Acad Sci U S A 103: 12487-1292.
43. Franchi L, Amer A, Body-Malapel M, Kanneganti TD, Ozoren N, et al. (2006) Cytosolic flagellin requires Ipaf for activation of caspase-1 and interleukin 1beta in salmonella-infected macrophages. Nat Immunol 7: 576-582.
44. Miao EA, puche-Aranda CM, Dors M, Clark AE, Bader MW, et al. (2006) Cytoplasmic flagellin activates caspase-1 and secretion of interleukin 1beta via Ipaf. Nat Immunol 7: 569-575.
45. Bobat S, Flores-Langarica A, Hitchcock J, Marshall JL, Kingsley RA, et al. (2011) Soluble flagellin, FliC, induces an Ag-specific Th2 response, yet promotes T-bet-regulated Th1 clearance of Salmonella Typhimurium infection. Eur J Immunol 41: 1606-18.
46. McSorley SJ, Cookson BT, Jenkins MK, (2000) Characterization of CD4+ T cell responses during natural infection with Salmonella typhimurium. J Immunol 164: 986-993.
47. Kodama C, Matsui H, (2004) Salmonella flagellin is not a dominant protective antigen in oral immunization with attenuated live vaccine strains. Infect Immun 72: 2449-2451.
48. Levine MM, (1994) Typhoid Fever Vaccines. In: Plotkin SA, Mortimer E, editors. Vaccines Philadelphia W. B. Saunders pp. 597-633.
49. Ashcroft MT, Nicholson CC, Balwant S, Ritchie JM, Sorvan E, et al. (1967) A seven-year field trial of two typhoid vaccines in Guiana. Lancet 2: 1056-1060.
50. Wahdan MH, Sippel JE, Mikhail IA, Rahka AE, Anderson ES, et al. (1975) Controlled field trial of a typhoid vaccine prepared with non-motile mutant of Salmonella typhi Ty2. Bull WHO 52: 69-73.
51. Didierlaurent A, Ferrero I, Otten LA, Dubois B, Reinhardt M, et al. (2004) Flagellin promotes myeloid differentiation factor 88-dependent development of Th2-type response. J Immunol 172: 6922-6930.
52. Honko AN, Mizel SB, (2004) Mucosal administration of flagellin induces innate immunity in the mouse lung. Infect Immun 72: 6676-6679.
53. Cunningham AF, Khan M, Ball J, Toellner KM, Serre K, et al. (2004) Responses to the soluble flagellar protein FliC are Th2, while those to FliC on Salmonella are Th1. Eur J Immunol 34: 2986-2995.
54. Kajikawa A, Igimi S, (2010) Innate and acquired immune responses induced by recombinant Lactobacillus casei displaying flagellin-fusion antigen on the cell-surface. Vaccine 28: 3409-3415.
55. Nimmerjahn F, Ravetch JV, (2008) Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 8: 34-47.
56. Peterson EM, Cheng X, Motin VL, de la Maza LM, (1997) Effect of immunoglobulin G isotype on the infectivity of Chlamydia trachomatis in a mouse model of intravaginal infection. Infect Immun 65: 2693-2699.
57. Muotiala A, Makela PH, (1993) Role of gamma interferon in late stages of murine salmonellosis. Infect Immun 61: 4248-4253.
58. Maclennan CA, Gondwe EN, Msefula CL, Kingsley RA, Thomson NR, et al. (2008) The neglected role of antibody in protection against bacteremia caused by nontyphoidal strains of Salmonella in African children. J Clin Invest 118: 1553-1562.
59. Gondwe EN, Molyneux ME, Goodall M, Graham SM, Mastroeni P, et al. (2010) Importance of antibody and complement for oxidative burst and killing of invasive nontyphoidal Salmonella by blood cells in Africans. Proc Natl Acad Sci U S A 107: 3070-3075.
60. Plotkin SA, (2010) Correlates of protection induced by vaccination. Clin Vaccine Immunol 17: 1055-1065.